EUVIMEDEUVIMED entdecken
Crossref

An analysis of the clinical value of CHI3L1 as a biomarker of multiple myeloma progression

Langui Tang, Juan Liang, Yazhou Huang, Kaiyun Guo, Yanzhao Huang, Yuxing He, Jun Wang, Ming Lei

Clinical Immunology · 2025

DOI: 10.1016/j.clim.2025.110474 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Immunology, 2025. Verfasst von Langui Tang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), China. Hauptthemen laut MEDLINE: Multiple Myeloma, Biomarkers, Tumor, Adipokines, Lectins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Hunan Provincial Natural Science Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: The aim of this study was to systematically assess the relationship between Chitinase 3-like protein-1 (CHI3L1) protein and disease progression in multiple myeloma (MM) and to explore its potential clinical value as a biomarker to provide a basis for optimizing treatment strategies. METHODS: 136 patients with MM were divided into two groups according to the efficacy: group 1-95 patients with non-progressing MM; group 2-41 patients with progressing MM. The concentration of CHI3L1 in the serum of the patients was determined by enzyme-linked immunosorbent assay (ELISA). RESULTS: CHI3L1 concentration in patients' serum was significantly greater than in healthy controls (P < 0.001), which patients with International Staging System (ISS) III had significantly higher CHI3L1 concentration than those with stage I/II. Patients in the progressed group had significantly higher CHI3L1 concentration than those in the non-progressed group by comparative analyses. Otherwise, multifactorial logistic regression analyses showed that CHI3L1 concentration was an independent predictor of MM progression after other confounding factors were excluded, and that the risk of progression in the high-concentration group was increased by 243.6 %, relative to the low-concentration group. Moreover, smoothed curve fitting analysis further confirmed that serum CHI3L1 concentration was linearly related to the probability of progression in MM patients, and the risk of progression increased as CHI3L1 concentration increased. CONCLUSIONS: This study indicated that CHI3L1 concentration in the serum of MM patients was closely correlated with disease severity. High concentration CHI3L1 predicted the progression of MM disease, suggesting its clinical application potential in predicting disease prognosis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaBiomarkers, TumorAdipokinesLectinsHumansChitinase-3-Like Protein 1FemaleMaleDisease ProgressionMiddle AgedAgedAdultAged, 80 and overPrognosisEnzyme-Linked Immunosorbent Assay

Stichwörter der Autor:innen

Chitinase-3-like protein-1Multiple myelomaPrognosisProgression

Substanzen

Chitinase-3-Like Protein 1CHI3L1 protein, humanBiomarkers, TumorAdipokinesLectins

Autor:innen und Institutionen

  • Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), China.
  • Hengyang Medical College, University of South China, China.
  • Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), China. Electronic address: angela80824w@sina.com.
  • Changde Hospital, Xiangya School of Medicine, Central South University (The First People's Hospital of Changde City), China. Electronic address: 285928388@csu.edu.cn.

Förderung

  • Hunan Provincial Natural Science Foundation

Zitieren

APA

Tang, L., Liang, J., Huang, Y., Guo, K., Huang, Y., He, Y., Wang, J., & Lei, M. (2025). An analysis of the clinical value of CHI3L1 as a biomarker of multiple myeloma progression. Clinical Immunology. https://doi.org/10.1016/j.clim.2025.110474

Vancouver

Tang L, Liang J, Huang Y, Guo K, Huang Y, He Y, et al. An analysis of the clinical value of CHI3L1 as a biomarker of multiple myeloma progression. Clinical Immunology. 2025. doi:10.1016/j.clim.2025.110474

BibTeX
@article{Tang2025,
  author = {Tang, Langui and Liang, Juan and Huang, Yazhou and Guo, Kaiyun and Huang, Yanzhao and He, Yuxing and Wang, Jun and Lei, Ming},
  title = {An analysis of the clinical value of CHI3L1 as a biomarker of multiple myeloma progression},
  journal = {Clinical Immunology},
  year = {2025},
  doi = {10.1016/j.clim.2025.110474}
}
Kostenlos starten →